Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis

Fertility and Sterility

Volumn 90, Issue 2, 2008, Pages 401-405

  Altintas, Devrim ^a   Kokcu, Arif ^a   Kandemir, Bedri ^a   Cetinkaya, Mehmet B ^a   Tosun, Migraci ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

experimental endometriosis; Imiquimod; immunomodulatory agent; rat

Indexed keywords

IMIQUIMOD; IMMUNOMODULATING AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIOSIS; ENDOMETRIUM; EXPERIMENTAL STUDY; FEMALE; HISTOPATHOLOGY; LAPAROTOMY; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; STROMA; WISTAR RAT;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 47849121738     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.06.057     Document Type: Article

References (34)

1. Braun D.P., and Dmowski W.P. Endometriosis: abnormal endometrium and dysfunctional immune response. Curr Opin Obstet Gynecol 10 (1998) 365-369
2. Somigliana E., Viganò P., and Vignali M. Endometriosis and unexplained recurrent spontaneous abortion: pathological states resulting from aberrant modulation of natural killer cell function?. Hum Reprod Update 5 (1999) 41-52
3. Semino C., Barrocci S., Semino A., Venturini P.L., Pietra G., Ragni N., et al. Role of major histocompatibility complex class I expression and natural killer-like T cells in the genetic control of endometriosis. Fertil Steril 64 (1995) 909-916
4. Story L., and Kennedy S. Animal studies in endometriosis: a review. ILAR J 45 (2004) 132-138
5. Garzetti G.G., Ciavattini A., Provinciali M., Muzzioli M., Di Stefano G., and Fabris N. Natural killer activity in stage III and IV endometriosis: impaired cytotoxicity and retained lymphokine responsiveness of natural killer cells. Gynecol Endocrinol 9 (1995) 125-130
6. D'Hooghe T.M., and Hill J.A. Endometriosis. In: Berek J.S. (Ed). Novak's gynecology. 13th ed. (2002), Lippincott Williams and Wilkins, Philadelphia 931-972
7. Memarzadeh S., Muse K.N., and Fox M.D. Endometriosis. In: DeCherney A.H., and Nathan L. (Eds). Current obstetric and gynecologic diagnosis and treatment. 9th ed (2003), Lange Medical Books/McGraw-Hill, New York 767-775
8. Otal H., Rong H., Igarashi S., and Tanakal T. Suppression of natural killer cell activity by splenocyte transplantation in a rat model of endometriosis. Hum Reprod 17 (2002) 1453-1458
9. D'Hooghe T.M., and Hill J.A. Immunology of endometriosis. In: Bronston R., and Anderson D.J. (Eds). Immunology of reproduction (1996), Blackwell Scientific, Cambridge, MA 322-356
10. Quaranta M.G., Porpora M.G., Mattioli B., Giordani L., Libri I., Ingelido A.M., et al. Impaired NK-cell-mediated cytotoxic activity and cytokine production in patients with endometriosis: a possible role for PCBs and DDE. Life Sci 79 (2006) 491-498
11. Siristatidis C., Nissotakis C., Chrelias C., Tacovidou H., and Salamalekis E. Immunological factors and their role in the genesis and development of endometriosis. J Obstet Gynaecol Res 32 (2006) 162-170
12. Braum D.P., Gebel H., Rotman C., Rana R., and Dmowski W.P. The development of cytotoxicity in peritoneal macrophages of women with endometriosis. Fertil Steril 57 (1992) 1203-1210
13. Nothnick W.B., Curry T.E., and Vernon M.W. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 31 (1994) 151-162
14. Vignali M., Infantino M., Matrone R., Chiado I., Somigliana E., Busacco M., et al. Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 78 (2002) 665-678
15. Ingelmo J.M., Quereda F., and Acien P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon α-2b in a murine model. Fertil Steril 71 (1999) 907-911
16. Ali A.F.M., Fateen B., Ezzet A., Badaway H., Ramadan A., and El-Tobge A. Laparoscopic intraperitoneal injection of human interferon α-2b in the treatment of pelvic endometriosis: a new modality. Obstet Gynecol 95 (2000) 47S-48S
17. Acien P., Quereda F., Campos A., Gomez-Torres M.J., Velasco I., and Gutierrez M. Use of intraperitoneal interferon α-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 78 (2002) 705-711
18. Keenan J.A., Williams-Boyce P.K., Massey P.J., Chen T.T., Caudle M.R., and Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 72 (1999) 135-141
19. Abdel-Haq N., Chearskul P., Al-Tatari H., and Asmar B. New antiviral agents. Indian J Pediatr 73 (2006) 313-321
20. Vidal D. Topical imiquimod: mechanism of action and clinical applications. Mini Rev Med Chem 6 (2006) 499-503
21. Mendonça C.O., and Yates V.M. Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol 31 (2006) 721-722
22. Nogueira S.A., Torres S.M., Malone E.D., Diaz S.F., Jessen C., and Gilbert S. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study. Vet Dermatol 17 (2006) 259-265
23. Brown M.G., Dokun A.O., Heusel J.W., Smith H.R., Beckman D.L., Blattenberger E.A., et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292 (2001) 934-937
24. Ferlazzo G., Thomas D., Lin S.L., Goodman K., Morandi B., Muller W.A., et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172 (2004) 1455-1462
25. Clement P.B. Diseases of the peritoneum. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract. 5th ed. (2002), Springer-Verlag, New York 729-789
26. Stefanaki C., Nicolaidou E., Hadjivassiliou M., Antoniou C., and Katsambas A. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 20 (2006) 755-756
27. Vun Y., and Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 47 (2006) 169-171
28. Goh M.S. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 47 (2006) 186-188
29. Garland S.M., Waddell R., Mindel A., Denham I.M., and McCloskey J.C. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 17 (2006) 448-452
30. Goldenberg G., Krowchuk D.P., and Jorizzo J.L. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 17 (2006) 121-123
31. Mirer E., El Sayed F., Ammoury A., Lamant L., Messer L., and Bazex J. Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. J Dermatolog Treat 17 (2006) 167-171
32. Rosen T. Limited extent AIDS-related cutaneous Kaposi's sarcoma responsive to imiquimod 5% cream. Int J Dermatol 45 (2006) 854-856
33. D'Addario S., and Carrington P.R. Multiple keratoacanthomas as an untoward response to imiquimod therapy for actinic keratoses. Acta Derm Venereol 86 (2006) 366-367
34. Bulbul Baskan E., Tunali S., Balaban Adim S., Turan A., and Toker S. A case of epidermodysplasia verruciformis associated with squamous cell carcinoma and Bowen's disease: a therapeutic challenge. J Dermatolog Treat 17 (2006) 179-183